Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.
Summary withdrawn
TitrateLab removes an AI-written study summary when it states findings we cannot trace to the study's own record, or when the study falls outside the compounds we track. Read the original record through the link above.
semaglutide
neuropsychiatric
obesity
t2dm
glp-1-agonist
cohort